Physician profile
Ju H Kim
NPI 1841426194
$7,120.31
in general payments reported to CMS, 2019-2025
24 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $1,029 · 2021: $354 · 2022: $1,318 · 2023: $1,509 · 2024: $874 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,603.01 | 2019-2025 | Impella |
| Abbott Laboratories | $2,200.66 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Triclip |
| Alnylam Pharmaceuticals INC. | $363.12 | 2019-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $354.10 | 2021-2024 | Optimizer, Optimizer |
| Actelion Pharmaceuticals US, INC. | $347.92 | 2019-2025 | Uptravi, Opsumit |
| Amgen INC. | $168.02 | 2019-2024 | Repatha |
| Biotronik INC. | $160.31 | 2022 | |
| Bridgebio Pharma, INC. | $137.25 | 2025 | Attruby |
| Zoll Respicardia, INC. | $123.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.29 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $98.11 | 2025 | Camzyos, Eliquis |
| Cvrx, INC. | $62.64 | 2024-2025 | Barostim Neo System |
| Pfizer INC. | $55.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $51.69 | 2021-2024 | Wainua, Farxiga |
| Tactile Systems Technology INC | $45.42 | 2022-2024 | Flexitouch Plus, Entre Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $41.87 | 2025 | |
| Medtronic, INC. | $38.63 | 2025 | Avalus |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2025 | Livtencity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.29 | 2025 | Lifevest |
| Haemonetics Corporation | $23.60 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.80 | 2023 | Inpefa |
| Novartis Pharmaceuticals Corporation | $18.83 | 2019 | |
| United Therapeutics Corporation | $14.51 | 2019 | |
| Medtronic Vascular, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ju Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.